News
A total of 2534 proposals were submitted in response to the ERC 2024 Advanced Grant Call (ERC-2024-ADG) with call deadline 29 August 2024. The preliminary data on submitted proposals for each domain is shown below:
Source: European Commission Funding and Tenders Portal
More details on submission statistics are included in the ERCEA news article
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
On 5 November 2026, the European Commission published a correction for Horizon Europe topic HORIZON-CL6-2027-02-FARM2FORK-05. Under the section ‘Topic description - Scope’, the sentence on collaboration with projects funded under other topics in the work programme has been updated. The original text referred to...
Read moreAre you planning to submit a proposal under the EDF-EDIP-USI-2026-LS-IRA-MAB call? (EDF Call for proposals for industrial reinforcement actions under the Ukraine Support Instrument)The European Commission has published a revised version of the call document, taking into account the possibility that additional funding may become available under...
Read moreThe new Digital Europe calls are expected to open in January 2027. Now is the time to look for your potential partners and form consortia.
Read moreThe 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
